Almost all technology projects face multiple risks that impact the project delivery across organizations. In this talk, you will learn the most important risks your technology projects can face and how strategies can be put in place to mitigate them and deliver as planned. Also learn the steps or process to manage risks to keep your projects on track. Good risk management means fewer issues, planned delivery and client confidence in your team to handle all uncertainties.

The pace of innovation in software and informatics is greatly outpacing most IT organizations. With regulatory agencies finally catching up (e.g., Computer Software Assurance in the FDA), business must build robust pipelines for evaluating, designing, testing, and deploying new applications let alone emerging technologies. Companies large and small can unlock their data pipeline by blending continuous integration with continuous improvement. Quality and DevOps principles can accelerate change, de-risk, technology and deliver quality data. In this talk, I discuss how I attack this problem from the perspective of culture and organizational habits. Giving the audience the wherewithal to change their teams and companies’ mindsets will help them evaluate the plethora of DevOps tools I introduce to meet their specific needs.

Authorization is a critical component of data systems that adhere to FAIR data principles. Distinct from authentication concerns (e.g. who is using the system), authorization engines answer the age-old data-governance question for data storage systems and applications: what information or resource(s) does the user have access to? Is the user permitted to perform an operation on this resource? In my talk titled "Authorization (AuthZ) Engine Architecture For Distributed Systems" I outline an ideal architecture for authorization engines in the context of distributed systems., including direction on avoiding common pitfalls relating to performance, capabilities, and architecture.

Automated regulatory compliance is a necessity in substance management. As a consequence of the spread of psychoactive substance derivatives, regulators increasingly use generic compound definitions, challenging conventional compliance verification methods. To solve this we have developed a novel search technology harnessing Markush structure queries, which increases the reliability of checking procedures.
We exhibit benchmarks against MolPort’s 45.8m compounds, and highlight the native scalability and integrability of the ComplianceChecker SaaS solution.

A lot of people feel stuck.  No one seems to have the power to change the status quo, no matter their title.  Why does it take so much time, effort and money to bring new therapies to market? Why can’t we change it, despite careers of effort? Apparently, we can change it. The urgency of the pandemic and the Warp Speed program proved that our constraints are self-imposed. In fact, the path to speed has been known for decades. But we, as an industry don't implement those solutions. It's time to change that. This talk will attack the problem with remedies at different levels, and will end with a tangible action that you can implement tomorrow. Disrupters, we need you. Change never happens until enough people stop believing that they’re stuck.

Nuclear Magnetic Resonance (NMR) is used in many stages of fragment-based drug discovery and design (FBDD), including for identifying lead drug-like molecules. In my presentation, I will document the role of NMR in FBDD and show how CcpNmr AnalysisScreen facilitates quality assessment of NMR data, and how robust and optimised workflows for automated rapid hit identification can be implemented, thus improving the speed, reliability, and reproducibility of the NMR-based FBDD process. AnalysisScreen is a modern, intuitive, and versatile biomolecular NMR software platform that enables easy analysis of the large datasets needed in the early process of drug discovery by NMR.

Collaborative Drug Discovery (CDD) provides a whole solution for today’s biological and chemical data needs, differentiated by ease-of-use and superior collaborative capabilities.  CDD Vault^® software includes Activity & Registration, Visualization, Inventory, and ELN capabilities. Researchers can archive, mine, and securely collaborate within CDD Vault.  Collaborative hypothesis generation and evaluation allow multiple perspectives for multi-parameter optimization.

Leading-organizations-are-developing-next-generation digital-strategies, including-adopting AI&ML tools. AI tools are cherries on the top of the cake of well-designed architectures, organizational behaviors, as well as deep scientific learning, and many organizations are only partly adapted to take full advantage of the possibilities. I will discuss the importance of standardized data management, enterprise integration tools, and how to enable better science via built-in analysis capabilities in a regulatory compliant, secure and auditable cloud offering.

In 2021, the European Union made major changes to its rules for international data transfers, changes that make it more much difficult to move research data out of the EU. Individual subject consent is getting heightened scrutiny, while use of the EU's Standard Contractual Clauses has become significantly more onerous, and impossible in some cases. This presentation will review these new roadblocks to research and explore the possibilities for overcoming them.

The Cures Act Final Rule requires all certified EHR systems to deliver a minimum set of clinical data (U.S. Core Data for Interoperability) by API for single patient or in bulk using the HL7 Fast Health Interoperability Resources (FHIR) data standard. Researchers will be able to complement their existing clinical data capture methods, especially if they need to assemble a longitudinal account of their participants medical history in the cohort. Learn how to exploit this approach as well as how other aspects of Final Rule will give researchers additional flexibility for acquiring more than the minimum set of clinical data.

Collecting clinical data for research can be difficult, especially when that data is spread across multiple healthcare institutions. Researchers are often forced to resort to incomplete participant surveys, time consuming record requests, and costly and error prone data re-keying. The HL7 FHIR data standard, built into dozens of electronic health record systems (EHRs) and deployed at thousands of healthcare institutions, enables novel, automated approaches to obtaining this data. Learn how FHIR's patient facing interfaces, provider facing interfaces, and bulk interfaces can be used by researchers to quickly get the data they need.

AI platform Cerella™ empowers discovery organisations, combining leading deep learning capabilities with an architecture designed for enterprise-level deployment. See how Cerella seamlessly integrates with frontend applications via a REST API, increasing adoption and augmenting existing workflows. Through a direct link to your corporate data infrastructure, Cerella automatically updates models and insights as new data become available, delivering proven technology and reducing the time and cost of drug discovery.